Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
Pegah Golabi, Munkhzul Otgonsuren, Leyla de Avila, et al.
Medicine (2018) Vol. 97, Iss. 13, pp. e0214-e0214
Open Access | Times Cited: 177

Showing 1-25 of 177 citing articles:

Non-alcoholic fatty liver disease – A global public health perspective
Zobair M. Younossi
Journal of Hepatology (2018) Vol. 70, Iss. 3, pp. 531-544
Open Access | Times Cited: 1786
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Zobair M. Younossi, Frank Tacke, Marco Arrese, et al.
Hepatology (2018) Vol. 69, Iss. 6, pp. 2672-2682
Open Access | Times Cited: 1580
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
Zobair M. Younossi, Pegah Golabi, James M. Paik, et al.
Hepatology (2023) Vol. 77, Iss. 4, pp. 1335-1347
Open Access | Times Cited: 1312
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1100
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Zobair M. Younossi, Maria Stepanova, Janus P. Ong, et al.
Clinical Gastroenterology and Hepatology (2018) Vol. 17, Iss. 4, pp. 748-755.e3
Open Access | Times Cited: 709
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 631
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Tracey G. Simon, Björn Roelstraete, Hamed Khalili, et al.
Gut (2020) Vol. 70, Iss. 7, pp. 1375-1382
Open Access | Times Cited: 463
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation
Zobair M. Younossi, Giulio Marchesini, Helena Pinto-Cortez, et al.
Transplantation (2018) Vol. 103, Iss. 1, pp. 22-27
Open Access | Times Cited: 351
AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review
Zobair M. Younossi, Kathleen E. Corey, Joseph K. Lim
Gastroenterology (2020) Vol. 160, Iss. 3, pp. 912-918
Closed Access | Times Cited: 351
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies
Helen Jarvis, Dawn Craig, Robert Barker, et al.
PLoS Medicine (2020) Vol. 17, Iss. 4, pp. e1003100-e1003100
Open Access | Times Cited: 324
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 254
Therapeutic pipeline in nonalcoholic steatohepatitis
Raj Vuppalanchi, Mazen Noureddin, Naim Alkhouri, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 6, pp. 373-392
Closed Access | Times Cited: 231
Challenges and opportunities in NASH drug development
Stephen A. Harrison, Alina M. Allen, Julie Dubourg, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 562-573
Closed Access | Times Cited: 192
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
Stephen A. Harrison, Naim Alkhouri, Beth A. Davison, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 4, pp. 613-626
Closed Access | Times Cited: 187
Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
James M. Paik, Linda Henry, Leyla de Avila, et al.
Hepatology Communications (2019) Vol. 3, Iss. 11, pp. 1459-1471
Open Access | Times Cited: 185
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Eun Jin Sun, Miriam Wankell, Pranavan Palamuthusingam, et al.
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1639-1639
Open Access | Times Cited: 173
Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD
Vy H. Nguyen, Michael H. Le, Ramsey Cheung, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 19, Iss. 10, pp. 2172-2181.e6
Closed Access | Times Cited: 172
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Zobair M. Younossi, Radhika P. Tampi, Andrei Racila, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 283-289
Open Access | Times Cited: 153
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 51
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
Pegah Golabi, James M. Paik, Ameeta Ravi Kumar, et al.
Metabolism (2023) Vol. 146, pp. 155642-155642
Closed Access | Times Cited: 43
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease
Zobair M. Younossi, Markos Kalligeros, Linda Henry
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 26
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David Le, Thomas C. Baez, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 2, pp. 235-246
Open Access | Times Cited: 24
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Zobair M. Younossi, Linda Henry
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 9-19
Open Access | Times Cited: 18
Food Insecurity, Low Household Income, and Low Education Level Increase the Risk of Having Metabolic Dysfunction–Associated Fatty Liver Disease Among Adolescents in the United States
James M. Paik, Sandy Duong, Shira Zelber‐Sagi, et al.
The American Journal of Gastroenterology (2024) Vol. 119, Iss. 6, pp. 1089-1101
Closed Access | Times Cited: 17
Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk
Agostino Di Ciaula, Jacek Baj, Gabriella Garruti, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 8, pp. 2648-2648
Open Access | Times Cited: 126
Page 1 - Next Page

Scroll to top